Interleukin-2 Suggested as Basis for Celiac Disease Diagnostic Test
By LabMedica International staff writers Posted on 19 Aug 2019 |
Image: A biopsy of small bowel showing celiac disease manifested by blunting of villi, crypt hypertrophy, and lymphocyte infiltration of crypts (Photo courtesy of Wikimedia Commons).
A study designed to link changes in cytokine release following ingestion of gluten by individuals suffering from celiac disease found that interleukin-2 (IL-2) was the earliest and most prominent cytokine.
Investigators at the biotechnology company ImmusanT (Cambridge, MA, USA), the Walter and Eliza Hall Institute (Melbourne, Australia), and collaborators in the United States and Norway were searching for biomarkers that could be used in a simple blood test for diagnosis of celiac disease.
Currently, diagnosis of celiac disease is typically made by a combination of blood antibody tests and intestinal biopsies, augmented by specific genetic testing. This approach is complicated by the fact that frequently the autoantibodies in the blood are negative, and many individuals have only minor intestinal changes with normal villi. Some celiac sufferers may have severe symptoms and be investigated for years before a diagnosis is achieved. Increasingly, diagnosis of celiac disease is being made in asymptomatic individuals, as a result of screening. Evidence regarding the effects of screening, however, has not been sufficient to determine its usefulness.
For the current study, the investigators injected celiac patients with gluten peptides, which induced gastrointestinal symptoms, particularly nausea and vomiting. In the second phase of the study, the patients consumed a diet including gluten.
Results revealed that peptide injection elevated at least 15 plasma cytokines, with IL-2, IL-8, and IL-10 being most prominent (fold-change increase at four hours of 272, 11, and 1.2, respectively). IL-2 and IL-8 were the only cytokines elevated at two hours, preceding onset of symptoms. After gluten ingestion, IL-2 was the earliest and most prominent cytokine (15-fold change at four hours).
Senior author Dr. Robert P. Anderson, chief scientific officer of ImmusanT, said, "For the first time we have described the inflammatory reaction that patients with celiac disease experience in the immediate hours after they are exposed to gluten. The unpleasant symptoms associated with the disease are linked to an increase in inflammatory molecules in the bloodstream, such as interleukin-2 (IL-2), produced by T-cells of the immune system. This response is similar to what happens when an infection is present, however for people with celiac disease, gluten is the trigger. This information underpins a potential new approach to diagnosis that addresses the emerging medical need to identify patients without celiac disease who may be better served by other treatments for their chronic symptoms."
Contributing author Dr. Jason Tye-Din, head of celiac research at the Walter and Eliza Hall Institute, said, "For the many people following a gluten-free diet without a formal diagnosis of celiac disease, all that might be required is a blood test before, and four hours after, a small meal of gluten. This would be a dramatic improvement on the current approach, which requires people to actively consume gluten for at least several weeks before undergoing an invasive procedure to sample the small intestine."
The study was published in the August 7, 2019, online edition of the journal Science Advances.
Related Links:
ImmusanT
Walter and Eliza Hall Institute
Investigators at the biotechnology company ImmusanT (Cambridge, MA, USA), the Walter and Eliza Hall Institute (Melbourne, Australia), and collaborators in the United States and Norway were searching for biomarkers that could be used in a simple blood test for diagnosis of celiac disease.
Currently, diagnosis of celiac disease is typically made by a combination of blood antibody tests and intestinal biopsies, augmented by specific genetic testing. This approach is complicated by the fact that frequently the autoantibodies in the blood are negative, and many individuals have only minor intestinal changes with normal villi. Some celiac sufferers may have severe symptoms and be investigated for years before a diagnosis is achieved. Increasingly, diagnosis of celiac disease is being made in asymptomatic individuals, as a result of screening. Evidence regarding the effects of screening, however, has not been sufficient to determine its usefulness.
For the current study, the investigators injected celiac patients with gluten peptides, which induced gastrointestinal symptoms, particularly nausea and vomiting. In the second phase of the study, the patients consumed a diet including gluten.
Results revealed that peptide injection elevated at least 15 plasma cytokines, with IL-2, IL-8, and IL-10 being most prominent (fold-change increase at four hours of 272, 11, and 1.2, respectively). IL-2 and IL-8 were the only cytokines elevated at two hours, preceding onset of symptoms. After gluten ingestion, IL-2 was the earliest and most prominent cytokine (15-fold change at four hours).
Senior author Dr. Robert P. Anderson, chief scientific officer of ImmusanT, said, "For the first time we have described the inflammatory reaction that patients with celiac disease experience in the immediate hours after they are exposed to gluten. The unpleasant symptoms associated with the disease are linked to an increase in inflammatory molecules in the bloodstream, such as interleukin-2 (IL-2), produced by T-cells of the immune system. This response is similar to what happens when an infection is present, however for people with celiac disease, gluten is the trigger. This information underpins a potential new approach to diagnosis that addresses the emerging medical need to identify patients without celiac disease who may be better served by other treatments for their chronic symptoms."
Contributing author Dr. Jason Tye-Din, head of celiac research at the Walter and Eliza Hall Institute, said, "For the many people following a gluten-free diet without a formal diagnosis of celiac disease, all that might be required is a blood test before, and four hours after, a small meal of gluten. This would be a dramatic improvement on the current approach, which requires people to actively consume gluten for at least several weeks before undergoing an invasive procedure to sample the small intestine."
The study was published in the August 7, 2019, online edition of the journal Science Advances.
Related Links:
ImmusanT
Walter and Eliza Hall Institute
Latest Molecular Diagnostics News
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection